Aerpio Pharmaceuticals Inc. [NASDAQ: ARPO] closed the trading session at $2.50 on 07/09/21. The day’s price range saw the stock hit a low of $2.28, while the highest price level was $2.54. The company report on July 10, 2021 that INVESTIGATION ALERT: Halper Sadeh LLP Investigates ONEM, SYKE, NETE, CHMA, SOLY, ARPO; Shareholders are Encouraged to Contact the Firm.
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:.
1Life Healthcare, Inc. (NASDAQ: ONEM) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with Iora Health. Under the terms of the merger, 1Life Healthcare will acquire Iora Health in an all-stock transaction. Upon closing, 1Life Healthcare shareholders are expected to own approximately 73.25% of the combined company. If you are a 1Life Healthcare shareholder, click here to learn more about your rights and options.
The stocks have a year to date performance of 155.10 percent and weekly performance of 42.05 percent. The stock has been moved at 121.24 percent over the last six months. The stock has performed 19.62 percent around the most recent 30 days and changed 85.19 percent over the most recent 3-months.
If compared to the average trading volume of 9.52M shares, ARPO reached to a volume of 20299695 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Aerpio Pharmaceuticals Inc. [ARPO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ARPO shares is $1.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ARPO stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BTIG Research have made an estimate for Aerpio Pharmaceuticals Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 09, 2020. While these analysts kept the previous recommendation, Needham raised their target price to Buy. The new note on the price target was released on July 23, 2018, representing the official price target for Aerpio Pharmaceuticals Inc. stock.
The Average True Range (ATR) for Aerpio Pharmaceuticals Inc. is set at 0.25, with the Price to Sales ratio for ARPO stock in the period of the last 12 months amounting to 8.81. The Price to Book ratio for the last quarter was 3.01, with the Price to Cash per share for the same quarter was set at 0.74.
ARPO stock trade performance evaluation
Aerpio Pharmaceuticals Inc. [ARPO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 42.05. With this latest performance, ARPO shares gained by 19.62% in over the last four-week period, additionally plugging by 121.24% over the last 6 months – not to mention a rise of 89.39% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ARPO stock in for the last two-week period is set at 66.49, with the RSI for the last a single of trading hit 68.87, and the three-weeks RSI is set at 64.64 for Aerpio Pharmaceuticals Inc. [ARPO]. The present Moving Average for the last 50 days of trading for this stock 1.70, while it was recorded at 2.10 for the last single week of trading, and 1.51 for the last 200 days.
Aerpio Pharmaceuticals Inc. [ARPO]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Aerpio Pharmaceuticals Inc. [ARPO] shares currently have an operating margin of -42.38. Aerpio Pharmaceuticals Inc.’s Net Margin is presently recorded at -28.77.
Return on Total Capital for ARPO is now -15.93, given the latest momentum, and Return on Invested Capital for the company is -10.83. Return on Equity for this stock declined to -10.84, with Return on Assets sitting at -10.17. When it comes to the capital structure of this company, Aerpio Pharmaceuticals Inc. [ARPO] has a Total Debt to Total Equity ratio set at 0.16. Additionally, ARPO Total Debt to Total Capital is recorded at 0.16, with Total Debt to Total Assets ending up at 0.15.
Reflecting on the efficiency of the workforce at the company, Aerpio Pharmaceuticals Inc. [ARPO] managed to generate an average of -$359,610 per employee.Aerpio Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 19.30 and a Current Ratio set at 19.30.
Aerpio Pharmaceuticals Inc. [ARPO]: Insider Ownership positions
There are presently around $66 million, or 73.70% of ARPO stock, in the hands of institutional investors. The top three institutional holders of ARPO stocks are: SATTER MANAGEMENT CO., L.P. with ownership of 5,621,835, which is approximately 0% of the company’s market cap and around 0.80% of the total institutional ownership; ORBIMED ADVISORS LLC, holding 5,193,946 shares of the stock with an approximate value of $12.98 million in ARPO stocks shares; and IKARIAN CAPITAL, LLC, currently with $6.63 million in ARPO stock with ownership of nearly 457.212% of the company’s market capitalization.
Positions in Aerpio Pharmaceuticals Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 20 institutional holders increased their position in Aerpio Pharmaceuticals Inc. [NASDAQ:ARPO] by around 8,374,490 shares. Additionally, 18 investors decreased positions by around 1,580,760 shares, while 12 investors held positions by with 16,608,200 shares. The mentioned changes placed institutional holdings at 26,563,450 shares, according to the latest SEC report filing. ARPO stock had 10 new institutional investments in for a total of 4,450,643 shares, while 8 institutional investors sold positions of 407,083 shares during the same period.